I thought we would discuss today the whole issue of the new medications for diabetes. We call them new but they're not that new. We're talking about the GLP-1 receptor agonists that have actually been on the market for 17 years. The long-acting ones have been on the market for 15 years. We are also discussing the new SGLT2 inhibitors that came to the market in 2013, so that's 9 years. These drugs are not new anymore. The reason we keep saying "new" is because of the outcomes of recent trials which show that these drugs, which were initially for glucose control, actually have cardiovascular and kidney benefits. We say "new" even though the results are not so new, with outcomes starting to be reported in 2015. If we count, it's already 7 years. Nothing is new in medicine nowadays when we receive double the information every 3 months or so. www.medscape.com/viewarticle/...